The most common treatment-related adverse events ( AEs ) with lubiprostone and placebo were nausea ( 16.8 % vs 5.8 % , respectively ) , diarrhea ( 9.6 % vs 2.9 % ) , and abdominal distention ( 8.2 % vs 2.4 % ) .